Table 3. Main ocular adverse events and systemic adverse events.

Adverse events	Combination group		PDT group		IVR group
	RCT (N=19)	RS (N=58)	RCT (N=21)	RS (N=140)	RCT (N=21)	RS (N=66)
	6mo	24mo	6mo	24mo	6mo	24mo
Ocular AEs
Retinal hemorrhage a	2 (10.5)	0	3 (14.3)	22 (15.8)	0	2 (3.0)
RPE detachment or subretinal fluid	0	1 (1.7)	0	0	0	9 (13.6)
RPE atrophy	0		0	2 (1.4)	0	2 (3.0)
Macular scar	1 (5.3)		0	1 (0.7)	1 (4.8)	2 (3.0)
Macular edema	1 (5.3)		0		0
Epiretinal membrane	0	0	0	0	0	2 (3.0)
Vitreous hemorrhage	0		1 (4.8)		0
Intraocular pressure increased	1 (5.3)	0	1 (4.8)	0	1 (4.8)	0
Conjunctival hemorrhage	0		0		1 (4.8)
Conjunctival hyperemia	1 (5.3)		0		0
Dry eye	1 (5.3)		1 (4.8)		0
VA reduced or impairment	1 (5.3)		0	0	1 (4.8)
Asthenopia	0		1 (4.8)		0
Non-ocular AEs
Angina pectoris	0		0		1 (4.8)
Noncardiac chest pain	0		1 (4.8)		0
Blood pressure increased	1 (5.3)		1 (4.8)		1 (4.8)
Gastric cancer	0		1 (4.8)		0
Vomiting	1 (5.3)		0		1 (4.8)
Abdominal pain	0		0		1 (4.8)
Nasopharyngitis	1 (5.3)		4 (19.0)		0
Dyspnoea	2 (10.5)		0		0
Dizziness	0		0		1 (4.8)

^aInclude intraretinal, subretinal, and subretinal pigment epithelium hemorrhage; N: No. of total patients; n: No. of eyes with adverse events; %: Incidence of adverse events; AEs: Adverse events; RPE: Retinal pigment epithelium; VA: Visual acuity.

n (%)